Blue Trust Inc. Purchases 186 Shares of West Pharmaceutical Services, Inc. (NYSE:WST)

Blue Trust Inc. boosted its position in West Pharmaceutical Services, Inc. (NYSE:WST) by 332.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 242 shares of the medical instruments supplier’s stock after acquiring an additional 186 shares during the period. Blue Trust Inc.’s holdings in West Pharmaceutical Services were worth $80,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in WST. International Assets Investment Management LLC lifted its stake in West Pharmaceutical Services by 13,230.0% in the fourth quarter. International Assets Investment Management LLC now owns 18,662 shares of the medical instruments supplier’s stock valued at $6,571,000 after buying an additional 18,522 shares during the period. Cerity Partners LLC lifted its stake in West Pharmaceutical Services by 44.8% in the fourth quarter. Cerity Partners LLC now owns 1,741 shares of the medical instruments supplier’s stock valued at $613,000 after buying an additional 539 shares during the period. Lindbrook Capital LLC lifted its stake in West Pharmaceutical Services by 46.0% in the fourth quarter. Lindbrook Capital LLC now owns 235 shares of the medical instruments supplier’s stock valued at $83,000 after buying an additional 74 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd lifted its stake in West Pharmaceutical Services by 1.5% in the fourth quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 6,437 shares of the medical instruments supplier’s stock valued at $2,267,000 after buying an additional 98 shares during the period. Finally, New York State Common Retirement Fund lifted its stake in West Pharmaceutical Services by 1.0% in the fourth quarter. New York State Common Retirement Fund now owns 137,112 shares of the medical instruments supplier’s stock valued at $48,280,000 after buying an additional 1,352 shares during the period. Institutional investors and hedge funds own 93.90% of the company’s stock.

West Pharmaceutical Services Trading Up 1.7 %

NYSE:WST opened at $304.31 on Thursday. The firm has a market capitalization of $22.07 billion, a price-to-earnings ratio of 40.15, a PEG ratio of 10.68 and a beta of 1.00. The company has a current ratio of 2.34, a quick ratio of 1.68 and a debt-to-equity ratio of 0.03. The business’s 50-day moving average price is $313.88 and its two-hundred day moving average price is $348.63. West Pharmaceutical Services, Inc. has a 1-year low of $265.00 and a 1-year high of $415.73.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings results on Thursday, July 25th. The medical instruments supplier reported $1.52 EPS for the quarter, missing analysts’ consensus estimates of $1.74 by ($0.22). The business had revenue of $702.10 million for the quarter, compared to analyst estimates of $729.36 million. West Pharmaceutical Services had a return on equity of 19.17% and a net margin of 18.25%. The company’s revenue for the quarter was down 6.9% compared to the same quarter last year. During the same period in the prior year, the business earned $2.11 EPS. On average, equities analysts expect that West Pharmaceutical Services, Inc. will post 6.44 earnings per share for the current year.

Insider Transactions at West Pharmaceutical Services

In other news, SVP Silji Abraham sold 1,800 shares of the firm’s stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $330.78, for a total transaction of $595,404.00. Following the sale, the senior vice president now owns 2,860 shares of the company’s stock, valued at $946,030.80. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, SVP Silji Abraham sold 1,800 shares of the stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $330.78, for a total transaction of $595,404.00. Following the completion of the transaction, the senior vice president now directly owns 2,860 shares in the company, valued at $946,030.80. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Charles Witherspoon sold 1,029 shares of the stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $300.00, for a total value of $308,700.00. Following the transaction, the vice president now owns 1,478 shares of the company’s stock, valued at $443,400. The disclosure for this sale can be found here. 0.53% of the stock is currently owned by insiders.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.